EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps

Robert L Dubin iD, Tierra N Sanders, Hunter M Schwab, Steven B Heymsfield iD, Frank L Greenway

Obesity · 2026

DOI: 10.1002/oby.70212 ↗

At a glance

Übersichtsarbeit in Obesity, 2026. Written by Robert L Dubin and 4 co-authors. Institution: Pennington Biomedical Research Center, Louisiana State University Health Sciences, Baton Rouge, Louisiana, USA. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Body Composition, Obesity, Anti-Obesity Agents. Cited 3 times so far (Crossref); 98 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can be quantified by changes in percent fat/fat‐free mass as a total of body weight. The amount of weight that is lost as % fat‐free mass (% FFML) with diet‐induced weight loss is ~25% but is extremely variable. Our aim was to provide an update to our previous report assessing changes in body composition using GLP‐1 RA‐based agents. In our updated review of 40 DXA‐based reports, we found the mean (SD) % FFML was 29.1% (19.0%). Similar to our previous report, we found that the changes in body composition using these agents remain in the upper range of expected % FFML using other nonsurgical interventions for obesity. Functional measures of strength and performance and assessing body composition effects of future GLP‐1‐based agents are needed to understand the continued gaps that exist in determining the impact these treatments have, particularly in high‐risk populations.

Subjects

MeSH terms (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsBody CompositionObesityAnti-Obesity AgentsHumansWeight LossGlucagon-Like Peptide-1 ReceptorExenatideSemaglutidePeptidesLiraglutideTirzepatideVenoms

Substances

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 ReceptorAnti-Obesity AgentsExenatideSemaglutidePeptidesLiraglutideTirzepatideVenoms

Authors and institutions

  • Pennington Biomedical Research Center, Louisiana State University Health Sciences, Baton Rouge, Louisiana, USA.

ORCID profiles: Robert L Dubin, Steven B Heymsfield

Cite

APA

Dubin, R. L., Sanders, T. N., Schwab, H. M., Heymsfield, S. B., & Greenway, F. L. (2026). Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps. Obesity. https://doi.org/10.1002/oby.70212

Vancouver

Dubin RL, Sanders TN, Schwab HM, Heymsfield SB, Greenway FL. Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps. Obesity. 2026. doi:10.1002/oby.70212

BibTeX
@article{Dubin2026,
  author = {Dubin, Robert L and Sanders, Tierra N and Schwab, Hunter M and Heymsfield, Steven B and Greenway, Frank L},
  title = {Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps},
  journal = {Obesity},
  year = {2026},
  doi = {10.1002/oby.70212}
}
Start for free →